Birch Hill Investment Advisors LLC raised its holdings in Laboratory Corporation of America Holdings (NYSE:LH) by 3.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 56,497 shares of the medical research company’s stock after buying an additional 2,098 shares during the quarter. Birch Hill Investment Advisors LLC owned about 0.06% of Laboratory Corporation of America Holdings worth $8,709,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of LH. UBS Asset Management Americas Inc. grew its position in shares of Laboratory Corporation of America Holdings by 1.7% in the 1st quarter. UBS Asset Management Americas Inc. now owns 905,278 shares of the medical research company’s stock worth $129,880,000 after buying an additional 15,137 shares during the last quarter. TD Asset Management Inc. lifted its stake in shares of Laboratory Corporation of America Holdings by 3.8% in the 1st quarter. TD Asset Management Inc. now owns 40,793 shares of the medical research company’s stock valued at $5,852,000 after purchasing an additional 1,506 shares during the period. Check Capital Management Inc. CA lifted its stake in shares of Laboratory Corporation of America Holdings by 16.2% in the 1st quarter. Check Capital Management Inc. CA now owns 266,633 shares of the medical research company’s stock valued at $38,254,000 after purchasing an additional 37,076 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of Laboratory Corporation of America Holdings by 28.5% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 7,588 shares of the medical research company’s stock valued at $1,089,000 after purchasing an additional 1,684 shares during the period. Finally, Toronto Dominion Bank lifted its stake in shares of Laboratory Corporation of America Holdings by 55.5% in the 1st quarter. Toronto Dominion Bank now owns 27,613 shares of the medical research company’s stock valued at $3,961,000 after purchasing an additional 9,857 shares during the period. Hedge funds and other institutional investors own 93.19% of the company’s stock.

In other Laboratory Corporation of America Holdings news, insider Lisa J. Uthgenannt sold 5,000 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $160.00, for a total transaction of $800,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO David P. King sold 132,713 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $157.06, for a total value of $20,843,903.78. The disclosure for this sale can be found here. In the last three months, insiders sold 222,968 shares of company stock worth $34,980,922. 0.90% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: “Laboratory Corporation of America Holdings (LH) Stake Raised by Birch Hill Investment Advisors LLC” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/18/laboratory-corporation-of-america-holdings-lh-stake-raised-by-birch-hill-investment-advisors-llc.html.

Shares of Laboratory Corporation of America Holdings (NYSE LH) traded up 0.44% on Monday, reaching $154.27. The company’s stock had a trading volume of 80,780 shares. The firm has a market capitalization of $15.70 billion, a PE ratio of 21.61 and a beta of 0.94. The firm has a 50-day moving average price of $156.60 and a 200 day moving average price of $147.65. Laboratory Corporation of America Holdings has a one year low of $119.51 and a one year high of $164.22.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The company had revenue of $2.50 billion for the quarter, compared to analysts’ expectations of $2.47 billion. During the same quarter in the prior year, the firm earned $2.36 earnings per share. Laboratory Corporation of America Holdings’s revenue was up 4.9% compared to the same quarter last year. On average, analysts anticipate that Laboratory Corporation of America Holdings will post $9.54 earnings per share for the current fiscal year.

LH has been the subject of a number of research analyst reports. Craig Hallum restated a “buy” rating and issued a $179.00 target price (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Thursday, July 27th. Credit Suisse Group restated a “buy” rating and issued a $146.00 target price on shares of Laboratory Corporation of America Holdings in a research note on Sunday, May 28th. Morgan Stanley raised their target price on Laboratory Corporation of America Holdings from $154.00 to $166.00 and gave the company an “overweight” rating in a research note on Thursday, August 10th. BidaskClub upgraded Laboratory Corporation of America Holdings from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, June 28th. Finally, Robert W. Baird restated a “hold” rating on shares of Laboratory Corporation of America Holdings in a research note on Sunday. Five research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $164.00.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corporation of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Stock Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related stocks with our FREE daily email newsletter.